Abstract: New RNases, and methods for making them, are disclosed. Each includes an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue or leader sequence.
Abstract: A new RNase, and a method for making it, are disclosed. The RNase has an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue.
Abstract: New RNases, and methods of making them, are disclosed. Each includes an amino acid sequence that is disclosed in U.S. Pat. No. 6,239,257 B1, but that is preceded by a different N-terminus residue or leader sequence.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.
Abstract: A nucleic acid encodes a novel fusion protein. The fusion protein contains a cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in United States Patent U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a leader sequence.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a leader sequence.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue.
Abstract: A nucleic acid encodes a novel fusion protein. The fusion protein contains a cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.
Abstract: A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in United States Patent U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence.
Abstract: A cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1 is disclosed. A targeting moiety can be conjugated to the cysteine residue.
Abstract: A cysteinized variant of an RNase disclosed in U.S. Pat. No. 6,239,257 B1 is disclosed. A targeting moiety can be conjugated to the cysteine residue.
Abstract: Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.
Abstract: Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.